InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective on the stock.

InspireMD Price Performance

NSPR stock opened at $2.72 on Tuesday. The firm has a 50 day simple moving average of $2.80 and a two-hundred day simple moving average of $2.72. The stock has a market cap of $70.94 million, a PE ratio of -3.63 and a beta of 0.99. InspireMD has a one year low of $1.81 and a one year high of $3.42.

InspireMD (NYSE:NSPR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The company had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. During the same period in the previous year, the business earned ($0.15) earnings per share. On average, research analysts expect that InspireMD will post -0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC bought a new stake in shares of InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned 0.42% of InspireMD at the end of the most recent reporting period. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.